Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced its participation in two upcoming investor conferences.

Rhea-AI Summary

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced its participation in two upcoming investor conferences. Management will present at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 p.m. ET, and at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 11:20 a.m. ET. Live webcasts of these presentations will be available on Milestone's website, with archived replays accessible for 90 days post-event. Milestone focuses on innovative cardiovascular medicines, with its lead candidate, etripamil, in Phase 3 trials for paroxysmal supraventricular tachycardia.

Argus Session date unavailable

-1.01% session move Open Argus

Details

News Market Reaction – MIST

The recorded move for MIST in the trading session of this news was -1.01%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MONTREAL and CHARLOTTE, N.C., March 1, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of management will present at the following investor conferences:

• The Cowen 42^nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:10 p.m. ET.
• The Oppenheimer 32^nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 11:20 a.m. ET.

A live webcast of each presentation can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of each webcast will be available on the same website for approximately 90 days following the presentation.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma.

Contact

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-upcoming-investor-conferences-301491773.html

SOURCE Milestone Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Milestone Pharmaceuticals presenting at the Cowen Annual Health Care Conference?

Milestone Pharmaceuticals will present at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 p.m. ET.

What is the date and time of Milestone Pharmaceuticals' presentation at the Oppenheimer Conference?

The presentation at the Oppenheimer 32nd Annual Healthcare Conference is on March 16, 2022, at 11:20 a.m. ET.

Where can I watch the presentations by Milestone Pharmaceuticals at the upcoming conferences?

The presentations will be available via live webcast on Milestone's website.

What is the main product being developed by Milestone Pharmaceuticals?

Milestone's lead candidate, etripamil, is in Phase 3 clinical trials for treating paroxysmal supraventricular tachycardia (PSVT).

How long will the archived webcasts of Milestone Pharmaceuticals' presentations be available?

Archived replays of the webcasts will be available for approximately 90 days after each presentation.